Infinity Pharmaceuticals shares 'too cheap to ignore,' says Piper Jaffray

Piper Jaffray recommends buying Infinity Pharmaceuticals shares after the company's ASCO oral presentation of IPI-145 Phase I data in lymphoma patients. Piper says shares are "too cheap to ignore" and keeps an Overweight rating on the name with a $50 price target.